Loss of PHD3 allows tumours to overcome hypoxic growth inhibition and sustain proliferation through EGFR

Anne-Theres Henze, Boyan K. Garvalov, Sascha Seidel, Angel M. Cuesta, Mathias Ritter, Alina Filatova, Franziska Foss, Higinio Dopeso, Clara L. Essmann, Patrick H. Maxwell, Guido Reifenberger, Peter Carmeliet, Amparo Acker-Palmer () and Till Acker ()
Additional contact information
Anne-Theres Henze: Institute of Neuropathology, University of Giessen
Boyan K. Garvalov: Institute of Neuropathology, University of Giessen
Sascha Seidel: Institute of Neuropathology, University of Giessen
Angel M. Cuesta: Institute of Cell Biology and Neuroscience, Buchmann Institute for Molecular Life Sciences (BMLS), University of Frankfurt
Mathias Ritter: Institute of Cell Biology and Neuroscience, Buchmann Institute for Molecular Life Sciences (BMLS), University of Frankfurt
Alina Filatova: Institute of Neuropathology, University of Giessen
Franziska Foss: Institute of Cell Biology and Neuroscience, Buchmann Institute for Molecular Life Sciences (BMLS), University of Frankfurt
Higinio Dopeso: Institute of Neuropathology, University of Giessen
Clara L. Essmann: Institute of Cell Biology and Neuroscience, Buchmann Institute for Molecular Life Sciences (BMLS), University of Frankfurt
Patrick H. Maxwell: Cambridge Institute for Medical Research, University of Cambridge
Guido Reifenberger: Institute of Neuropathology, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)
Peter Carmeliet: Vesalius Research Center (VRC), Angiogenesis and Neurovascular Link Laboratory, University of Leuven
Amparo Acker-Palmer: Institute of Cell Biology and Neuroscience, Buchmann Institute for Molecular Life Sciences (BMLS), University of Frankfurt
Till Acker: Institute of Neuropathology, University of Giessen

Nature Communications, 2014, vol. 5, issue 1, 1-12

Abstract: Abstract Solid tumours are exposed to microenvironmental factors such as hypoxia that normally inhibit cell growth. However, tumour cells are capable of counteracting these signals through mechanisms that are largely unknown. Here we show that the prolyl hydroxylase PHD3 restrains tumour growth in response to microenvironmental cues through the control of EGFR. PHD3 silencing in human gliomas or genetic deletion in a murine high-grade astrocytoma model markedly promotes tumour growth and the ability of tumours to continue growing under unfavourable conditions. The growth-suppressive function of PHD3 is independent of the established PHD3 targets HIF and NF-κB and its hydroxylase activity. Instead, loss of PHD3 results in hyperphosphorylation of epidermal growth factor receptor (EGFR). Importantly, epigenetic/genetic silencing of PHD3 preferentially occurs in gliomas without EGFR amplification. Our findings reveal that PHD3 inactivation provides an alternative route of EGFR activation through which tumour cells sustain proliferative signalling even under conditions of limited oxygen availability.

Date: 2014
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/ncomms6582 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:5:y:2014:i:1:d:10.1038_ncomms6582

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms6582

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().